HIV, Tat and dopamine transmission
Human Immunodeficiency Virus (HIV) is a progressive infection that targets the immune system, affecting more than 37 million people around the world. While combinatorial antiretroviral therapy (cART) has lowered mortality rates and improved quality of life in infected individuals, the prevalence of...
Main Authors: | Peter J. Gaskill, Douglas R. Miller, Joyonna Gamble-George, Hideaki Yano, Habibeh Khoshbouei |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S096999611730089X |
Similar Items
-
Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders
by: Silvia Zucchini, et al.
Published: (2013-07-01) -
Role of FOXO3 Activated by HIV-1 Tat in HIV-Associated Neurocognitive Disorder Neuronal Apoptosis
by: Huaqian Dong, et al.
Published: (2019-02-01) -
HIV-1 Tat neurotoxicity: A model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes
by: Lokesh Agrawal, et al.
Published: (2012-02-01) -
Heterogeneity of dopamine release sites in health and degeneration
by: Joseph J. Lebowitz, et al.
Published: (2020-02-01) -
Inhibition of GABAergic Neurotransmission by HIV-1 Tat and Opioid Treatment in the Striatum Involves μ-opioid Receptors
by: Changqing Xu, et al.
Published: (2016-11-01)